Table 4. Summary of Messenger RNA-Based SARS-CoV-2 Vaccination Status in Singapore as of June 22, 2021.
| Characteristic | Vaccine, No. | Total | |
|---|---|---|---|
| BNT162b2 (Pfizer-BioNTech) | mRNA-1273 (Moderna) | ||
| Participants, No. (cumulative duration of exposure, person-years)a | |||
| Who received at least 1 dose of vaccine | 2 283 221 (263 449) | 723 441 (83 474) | 3 006 662 (346 923) |
| Who received both doses of vaccine | 1 733 611 (200 032) | 334 499 (38 596) | 2 068 110 (238 628) |
| Who only received 1 dose of vaccine | 549 610 (63 417) | 388 942 (44 878) | 938 552 (108 294) |
| Total doses of vaccine administered, No. | 4 016 832 | 1 057 940 | 5 074 772 |
| Receiving only 1 dose | |||
| No. of hospitalized CVT cases | 1 | 1 | 2 |
| Annualized incidence rate of hospitalized CVT cases per 100 000 person-years (95% CI) | 1.58 (0.04-8.79) | 2.23 (0.06-12.4) | 1.85 (0.22-6.67) |
| Receiving both doses | |||
| No. of hospitalized CVT cases | 5 | 2 | 7 |
| Annualized incidence rate of hospitalized CVT cases, per 100 000 person-years (95% CI) | 2.50 (0.81-5.83) | 5.18 (0.63-18.7) | 2.93 (1.18-6.04) |
| Receiving at least 1 dose | |||
| No. of hospitalized CVT cases | 6 | 3 | 9 |
| Annualized incidence rate of hospitalized CVT cases, per 100 000 person-years (95% CI) | 2.28 (0.84-4.96) | 3.59 (0.74-10.5) | 2.59 (1.19-4.92) |
Abbreviation: CVT, cerebral venous thrombosis.
a
Exposure was calculated based on 6 weeks after last dose of vaccine.